Paper Details

  1. Home
  2. Paper Details

Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.

Author: HeymannsJ, KöpplerH, WeideR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Patients receiving paclitaxel often receive premedication with dexamethasone, ranitidine, and clemastine to prevent allergic reactions. The standard dexamethasone dose is 20 mg given orally 12 and 6 hours before paclitaxel. However, a single intravenous dose of 40 mg given just before paclitaxel is equally effective. To potentially reduce steroid side effects, especially in patients receiving weekly paclitaxel treatments, this study investigates reducing the dexamethasone dose.
Paper Details　
Original Abstract of the Article :
Premedication with dexamethasone, ranitidine and clemastine is mandatory for patients receiving paclitaxel to avoid hypersensitivity reactions. The proposed dexamethasone dose is 20 mg orally 12 and 6 h prior to paclitaxel infusion. With this premedication severe hypersensitivity reactions are reduc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000055093

データ提供：米国国立医学図書館（NLM）

Exploring the Potential of Reducing Steroid Premedication for Paclitaxel

This research explores the possibility of reducing the dexamethasone dose used as premedication for paclitaxel, a chemotherapy drug commonly used to treat various cancers. Dexamethasone is typically administered to prevent hypersensitivity reactions, a common side effect of paclitaxel. The researchers investigated whether reducing the dexamethasone dose would lead to an increase in hypersensitivity reactions. Their findings were reassuring, demonstrating that a reduced dexamethasone dose did not increase the incidence of these reactions.

Striving for Balance: Minimizing Side Effects While Maintaining Efficacy

This study highlights the ongoing search for ways to minimize the side effects of chemotherapy drugs while maintaining their efficacy. The researchers' findings suggest that a reduced dexamethasone dose may be a viable option for some patients, particularly those receiving weekly paclitaxel protocols.

Personalized Chemotherapy: A Journey Towards Minimizing Side Effects

This research underscores the importance of personalized chemotherapy approaches that consider individual patient factors, such as the frequency of treatment and potential risks of steroid-induced side effects. By exploring alternative premedication strategies, researchers are working towards minimizing the burden of chemotherapy for patients, enabling them to receive effective treatment with fewer side effects.

Dr. Camel's Conclusion

This study provides valuable insights into the potential for reducing dexamethasone premedication for paclitaxel. The researchers' findings suggest that a reduced dexamethasone dose may be a viable option for some patients, offering a way to minimize steroid-induced side effects without compromising the efficacy of paclitaxel. The pursuit of personalized chemotherapy approaches that prioritize patient well-being is a vital step in improving the lives of cancer patients.

Date :
  1. Date Completed 2001-10-18
  2. Date Revised 2017-11-01
Further Info :

Pubmed ID

11455223

DOI: Digital Object Identifier

10.1159/000055093

Related Literature

Article Analysis
・Side Effects of ranitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.